

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF  
1934

September 10, 2019

**001-36686**  
(Commission file number)

**Forward Pharma A/S**  
(Translation of registrant's name into English)

**Østergade 24A, 1st Floor**  
**1100 Copenhagen K, Denmark**  
(Address of principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes  No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes  No

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

## Item 1. Other Items

Forward Pharma A/S (the “Company”) is submitting this Report on Form 6-K to provide its (i) interim condensed consolidated statement of financial position as of June 30, 2019, unaudited, and December 31, 2018 and (ii) unaudited interim condensed consolidated statements of profit or loss each of the six-month periods ended June 30, 2019 and 2018, which are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively. Exhibits 99.1 and 99.2 are furnished herewith solely for the purpose of meeting the requirements of Nasdaq Stock Market Rule 5250(c)(2) to submit an interim balance sheet and income statement as of the end of the Company’s second quarter.

### EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
<u>99.1*</u>	<u><a href="#">Interim condensed consolidated statement of Financial Position of the Company as of June 30, 2019, unaudited, and December 31, 2018</a></u>
<u>99.2*</u>	<u><a href="#">Unaudited interim condensed consolidated statement of Profit or Loss of the Company for each of the six-month periods ended June 30, 2019 and 2018</a></u>

\* Furnished herewith solely for the purpose of meeting the requirements under Nasdaq Stock Market Rule 5250(c)(2) in connection with submission of an interim balance sheet and income statement as of the end of its second quarter.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Date: September 10, 2019

Forward Pharma A/S

By: /s/ Claus Bo Svendsen

Name: Claus Bo Svendsen

Title: Chief Executive Officer

## Interim Condensed Consolidated Statement of Financial Position

as of June 30, 2019, Unaudited, and December 31, 2018

## Assets

	June 30, 2019 (Unaudited)	December 31, 2018
	USD `000	USD `000
Non-current Assets:		
Other non-current assets	2	2
Total non-current assets	<u>2</u>	<u>2</u>
Prepaid expenses	168	340
Other receivables	153	266
Income tax receivable	181	182
Cash and cash equivalents	80,169	82,542
Total current assets	<u>80,671</u>	<u>83,330</u>
Total assets	<u><u>80,673</u></u>	<u><u>83,332</u></u>

## Shareholders' Equity and Liabilities

	June 30, 2019 (Unaudited)	December 31, 2018
	USD `000	USD `000
Share capital	152	152
Other components of equity:		
Foreign currency translation reserve	87,253	87,748
Accumulated deficit	(7,397)	(5,686)
Equity attributable to shareholders of the Parent	<u>80,008</u>	<u>82,214</u>
Total shareholders' equity	<u>80,008</u>	<u>82,214</u>
Trade payables	207	428
Income tax payable	—	68
Accrued liabilities	458	622
Total current liabilities	<u>665</u>	<u>1,118</u>
Total shareholders' equity and liabilities	<u><u>80,673</u></u>	<u><u>83,332</u></u>

**Unaudited Interim Condensed Consolidated Statement of Profit or Loss**

**for the six-month periods ended June 30, 2019 and 2018**

**amounts in thousands except per share amounts**

	Six-Month Periods Ended June 30,	
	2019 USD	2018 USD
Research and development costs	(626)	(1,843)
General and administrative costs	(2,602)	(5,803)
Operating loss	(3,228)	(7,646)
Foreign exchange rate gain	187	1,859
Other finance income	191	313
Loss before taxes	(2,850)	(5,474)
Income tax benefit	—	204
Net loss for the period	(2,850)	(5,270)
Net loss for the period attributable to:		
Equity holders of the Parent	(2,850)	(5,270)
<i>Per share amounts:</i>		
<i>Net loss per share basic and diluted</i>	(0.03)	(0.06)